erlotinib has been researched along with aripiprazole in 2 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (aripiprazole) | Trials (aripiprazole) | Recent Studies (post-2010) (aripiprazole) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 2,989 | 509 | 1,788 |
| Protein | Taxonomy | erlotinib (IC50) | aripiprazole (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 0.78 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0158 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 1.945 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.38 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.17 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.42 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.8572 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
2 review(s) available for erlotinib and aripiprazole
| Article | Year |
|---|---|
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors | 2012 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |